Literature DB >> 9112356

Association between HLA-DPB1 matching and 1-year rejection-free graft survival in high-risk corneal transplantation.

B Munkhbat1, M Hagihara, T Sato, F Tsuchida, K Sato, J Shimazaki, K Tsubota, K Tsuji.   

Abstract

We analyzed the effect of matching for HLA class II alleles on corneal graft outcome in a single-center, retrospective study from January 1991 through April 1996. The study involved 81 transplant recipients at high and low risk of corneal graft rejection, who were typed by the polymerase chain reaction-restriction fragment length polymorphism method and who completed at least 1-year of follow-up. The DRB1, DQB1, and DPB1 alleles were analyzed together and transplant recipients were subdivided into groups with matching (one to four alleles matched in the high risk or one to five alleles matched in the low risk) and without matching (no allele matched) for HLA class II. A significantly higher rate of 1-year rejection-free graft survival was revealed in high-risk transplant recipients with matching, compared with those without matching (P=0.0238). We have shown that matching for at least one HLA class II allele was actually beneficial in high-risk transplants. An analysis of matching for each allele separately, detected that only HLA-DPB1 matching was significantly associated with a higher rate of 1-year rejection-free graft survival in high-risk transplant recipients with matching (one or two alleles matched) compared with those without matching (no allele matched) (P=0.0139). In particular, matching for one DPB1 allele was significantly beneficial compared with no matching (P=0.0140). There was no significant effect of HLA-DRB1 and -DQB1 matching (P=0.3177 and P=0.2878, respectively). Furthermore, a strong association between DPB1 matching and 1-year rejection-free graft survival was observed in DRB1-incompatible high-risk transplant recipients (P=0.0308). Nevertheless, no significant effect of DPB1 matching was detected in DQB1-incompatible transplant recipients. Our findings indicate that HLA class II DNA typing is clinically relevant for corneal transplant recipients and that especially HLA-DPB1 matching has a beneficial effect in high-risk corneal transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9112356     DOI: 10.1097/00007890-199704150-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  [Tissue typing in perforating corneal transplantation].

Authors:  J Wachtlin; R Khaireddin; F Hoffmann
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

2.  Rejection Prophylaxis in Corneal Transplant.

Authors:  Daniel Böhringer; Birgit Grotejohann; Gabriele Ihorst; Helga Reinshagen; Eric Spierings; Thomas Reinhard
Journal:  Dtsch Arztebl Int       Date:  2018-04-13       Impact factor: 5.594

3.  Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells.

Authors:  Junbao Yang; Laurel Huston; Deanna Berger; Nancy A Danke; Andrew W Liu; Mary L Disis; William W Kwok
Journal:  J Clin Immunol       Date:  2005-09       Impact factor: 8.317

4.  Influence of HLA-A, HLA-B, and HLA-DR matching on rejection of random corneal grafts using corneal tissue for retrospective DNA HLA typing.

Authors:  M C Bartels; H G Otten; B E van Gelderen; A Van der Lelij
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

5.  HLA-A, HLA-B and HLA-DR matching reduces the rate of corneal allograft rejection.

Authors:  Riad Khaireddin; Joachim Wachtlin; Werner Hopfenmüller; Friedrich Hoffmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-08-29       Impact factor: 3.117

6.  Genetic variants in major histocompatibility complex-linked genes associate with pediatric liver transplant rejection.

Authors:  Rakesh Sindhi; Brandon W Higgs; Daniel E Weeks; Chethan Ashokkumar; Ronald Jaffe; Cecilia Kim; Patrick Wilson; Nydia Chien; Joseph Glessner; Anjan Talukdar; George Mazariegos; M Michael Barmada; Edward Frackleton; Nancy Petro; Andrew Eckert; Hakon Hakonarson; Robert Ferrell
Journal:  Gastroenterology       Date:  2008-06-03       Impact factor: 22.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.